Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Balance of Treg vs. T-helper cells in the transition from symptomless to lesional psoriatic skin
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 168, Issue 6, Pages 1294-1302
Publisher
Wiley
Online
2013-01-21
DOI
10.1111/bjd.12236
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
- (2011) Troy Noordenbos et al. ARTHRITIS AND RHEUMATISM
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
- (2011) A. M. Lin et al. JOURNAL OF IMMUNOLOGY
- Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin
- (2011) H. Jorn Bovenschen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
- (2011) Heiner Appel et al. ARTHRITIS RESEARCH & THERAPY
- Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium
- (2011) Jolien Suurmond et al. ARTHRITIS RESEARCH & THERAPY
- Human regulatory T cells in autoimmune diseases
- (2010) Gregory L Cvetanovich et al. CURRENT OPINION IN IMMUNOLOGY
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overrepresentation of IL-17A and IL-22 Producing CD8 T Cells in Lesional Skin Suggests Their Involvement in the Pathogenesis of Psoriasis
- (2010) Pieter C. M. Res et al. PLoS One
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- Innate immunity and allergy in the skin
- (2009) Martin Metz et al. CURRENT OPINION IN IMMUNOLOGY
- Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis
- (2009) J T Elder GENES AND IMMUNITY
- CD39+Foxp3+ Regulatory T Cells Suppress Pathogenic Th17 Cells and Are Impaired in Multiple Sclerosis
- (2009) J. M. Fletcher et al. JOURNAL OF IMMUNOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis
- (2009) Frank O. Nestle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Distribution of dipeptidyl-peptidase IV on keratinocytes in the margin zone of a psoriatic lesion: a comparison with hyperproliferation and aberrant differentiation markers
- (2008) R. G. van Lingen et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells
- (2008) H. J. P. M. Koenen et al. BLOOD
- Possible Pathogenic Role of Th17 Cells for Atopic Dermatitis
- (2008) Chizuko Koga et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
- (2008) Michelle A. Lowes et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-21 and TGF-β are required for differentiation of human TH17 cells
- (2008) Li Yang et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started